BioMark Diagnostics Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BMKDF research report →
Price Chart
About the company
BioMark Diagnostics Inc. is an oncology-focused firm that develops sophisticated diagnostic tools for cancer. These solutions are designed to aid in the identification of the disease, its ongoing monitoring, and the assessment of initial therapeutic interventions.
- CEO
- Rashid Ahmed Maula Bux
- IPO
- 2015
- Employees
- 9
- HQ
- Richmond, BC, CA
Get TickerSpark's AI analysis on BMKDF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
- Market Cap
- $39.61M
- P/E
- -38.52
- PEG
- -1.12
- P/S
- 1965.50
- P/B
- 96.82
- EV/EBITDA
- -37.50
- Div Yield
- 0.00%
- Gross Margin
- -1273.73%
- Op Margin
- -6782.46%
- Net Margin
- -5127.11%
- ROE
- -250.77%
- ROIC
- -94.02%
Latest fiscal year · YoY change
- Revenue
- $59.79K-61.2%
- Gross Profit
- $59.79K-61.2%
- Op Income
- $-1,456,874
- Net Income
- $-1,477,195+23.4%
- EPS
- $-0.01+29.5%
- OCF Growth
- +0.4%
- FCF Growth
- +0.3%
- 52W High
- $0.50
- 52W Low
- $0.22
- 50D MA
- $0.38
- 200D MA
- $0.40
- Beta
- -0.31
- RSI (14)
- 48
- Avg Volume
- 3.09K
No earnings-call transcripts are available for BMKDF yet.
- Free Float
- 45.5%
- Shares Outstanding
- 105.09M
- Float Shares
- 47.84M
Our BMKDF coverage
Recent articles, reports, and earnings notes.
No research on BMKDF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate BMKDF report →BioMark Announces Participation in upcoming MSACL 2026 and BIOHorizon 2026 Life Sciences Conferences
newsfilecorp.com · Sep 21
BioMark's Metabolomics Platform Captures Global Scientific Interest Following Publications Demonstrating Superior Diagnostic Performance and Cost Efficiency for Liquid Biopsy
newsfilecorp.com · Aug 25
BioMark Diagnostics Endorses Global Call for Equitable Access to Early Screening on 2026 World Lung Cancer Day
newsfilecorp.com · Jul 31
BioMark Diagnostics Secures Landmark Canadian and European Patent Allowances for Early-Stage Lung Cancer Blood Test
newsfilecorp.com · Jun 23
BioMark Secures Broad U.S. Patent for Urine-Based Lung Cancer Screening, Expanding Differentiated Liquid Biopsy Testing Platform
newsfilecorp.com · Jun 9
BioMark Diagnostics to Present Liquid Biopsy Platform at the Canadian Thoracic Society Research Forum
newsfilecorp.com · Apr 14
BioMark Diagnostics Announces Publication of Peer-Reviewed Validation of Machine Learning Models for Lung Cancer Detection in Frontiers in Oncology
newsfilecorp.com · Jan 15
BioMark: 2025 Achievements & 2026 Vision
newsfilecorp.com · Dec 31
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.